Nektar Therapeutics (NKTR)
USD 0.56
(-6.09%)
USD 0.56
(-6.09%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 210.24 Million USD | 385.89% |
| 2022 | 43.26 Million USD | -63.32% |
| 2021 | 117.95 Million USD | 342.38% |
| 2020 | -48.66 Million USD | -115.82% |
| 2019 | 307.57 Million USD | 490.98% |
| 2018 | 52.04 Million USD | -78.35% |
| 2017 | 240.44 Million USD | 27.25% |
| 2016 | 188.95 Million USD | -1.78% |
| 2015 | 192.37 Million USD | 58.61% |
| 2014 | 121.28 Million USD | 29.05% |
| 2013 | 93.98 Million USD | -15.46% |
| 2012 | 111.17 Million USD | -48.11% |
| 2011 | 214.22 Million USD | 0.01% |
| 2010 | 214.21 Million USD | 16.32% |
| 2009 | 184.15 Million USD | 131.01% |
| 2008 | 79.71 Million USD | -69.65% |
| 2007 | 262.67 Million USD | -29.83% |
| 2006 | 374.36 Million USD | 111.34% |
| 2005 | 177.13 Million USD | 87.15% |
| 2004 | 94.65 Million USD | -71.25% |
| 2003 | 329.25 Million USD | 10.81% |
| 2002 | 297.14 Million USD | -1.3% |
| 2001 | 301.05 Million USD | 63.37% |
| 2000 | 184.27 Million USD | 130.46% |
| 1999 | 79.96 Million USD | 501.57% |
| 1998 | -19.91 Million USD | -103.95% |
| 1997 | -9.76 Million USD | 46.36% |
| 1996 | -18.2 Million USD | -468.75% |
| 1995 | -3.2 Million USD | 67.35% |
| 1994 | -9.8 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 197.19 Million USD | -6.21% |
| 2024 Q2 | 205.68 Million USD | 4.31% |
| 2023 Q2 | 74.02 Million USD | 44.55% |
| 2023 Q1 | 51.2 Million USD | 18.35% |
| 2023 FY | 210.24 Million USD | 385.89% |
| 2023 Q3 | 56.36 Million USD | -23.85% |
| 2023 Q4 | 210.24 Million USD | 272.98% |
| 2022 Q2 | 61.91 Million USD | -16.6% |
| 2022 Q3 | 28.89 Million USD | -53.33% |
| 2022 Q1 | 74.24 Million USD | -37.06% |
| 2022 FY | 43.26 Million USD | -63.32% |
| 2022 Q4 | 43.26 Million USD | 49.75% |
| 2021 Q4 | 117.95 Million USD | 27.6% |
| 2021 FY | 117.95 Million USD | 342.38% |
| 2021 Q1 | 160 Thousand USD | 100.33% |
| 2021 Q2 | -3.91 Million USD | -2544.38% |
| 2021 Q3 | 92.44 Million USD | 2463.62% |
| 2020 Q3 | 98.52 Million USD | -0.04% |
| 2020 Q2 | 98.56 Million USD | -46.73% |
| 2020 FY | -48.66 Million USD | -115.82% |
| 2020 Q4 | -48.66 Million USD | -149.39% |
| 2020 Q1 | 185.01 Million USD | -39.85% |
| 2019 FY | 307.57 Million USD | 490.98% |
| 2019 Q3 | 321.45 Million USD | 23.18% |
| 2019 Q4 | 307.57 Million USD | -4.32% |
| 2019 Q1 | 237.3 Million USD | 355.97% |
| 2019 Q2 | 260.96 Million USD | 9.97% |
| 2018 Q2 | -665.04 Million USD | -415.43% |
| 2018 Q4 | 52.04 Million USD | 114.59% |
| 2018 FY | 52.04 Million USD | -78.35% |
| 2018 Q1 | 210.83 Million USD | -12.31% |
| 2018 Q3 | 24.25 Million USD | 103.65% |
| 2017 FY | 240.44 Million USD | 27.25% |
| 2017 Q4 | 240.44 Million USD | 14.89% |
| 2017 Q3 | 209.28 Million USD | -9.77% |
| 2017 Q2 | 231.94 Million USD | 3.12% |
| 2017 Q1 | 224.93 Million USD | 19.04% |
| 2016 Q3 | 184.22 Million USD | -4.68% |
| 2016 Q1 | 177.68 Million USD | -7.63% |
| 2016 Q2 | 193.26 Million USD | 8.77% |
| 2016 FY | 188.95 Million USD | -1.78% |
| 2016 Q4 | 188.95 Million USD | 2.57% |
| 2015 Q4 | 192.37 Million USD | 69.64% |
| 2015 Q1 | 5.34 Million USD | -95.59% |
| 2015 Q3 | 113.39 Million USD | 0.66% |
| 2015 FY | 192.37 Million USD | 58.61% |
| 2015 Q2 | 112.65 Million USD | 2007.31% |
| 2014 FY | 121.28 Million USD | 29.05% |
| 2014 Q2 | 100.32 Million USD | 0.72% |
| 2014 Q3 | 98.33 Million USD | -1.99% |
| 2014 Q1 | 99.6 Million USD | 5.99% |
| 2014 Q4 | 121.28 Million USD | 23.34% |
| 2013 Q1 | 107.23 Million USD | -3.54% |
| 2013 Q3 | 68.59 Million USD | -26.61% |
| 2013 FY | 93.98 Million USD | -15.46% |
| 2013 Q4 | 93.98 Million USD | 37.01% |
| 2013 Q2 | 93.46 Million USD | -12.84% |
| 2012 Q3 | 127.07 Million USD | 38.16% |
| 2012 Q1 | 80.36 Million USD | -62.49% |
| 2012 FY | 111.17 Million USD | -48.11% |
| 2012 Q4 | 111.17 Million USD | -12.52% |
| 2012 Q2 | 91.97 Million USD | 14.45% |
| 2011 Q3 | 187.19 Million USD | -14.6% |
| 2011 Q2 | 219.19 Million USD | 4.92% |
| 2011 Q1 | 208.91 Million USD | -2.47% |
| 2011 FY | 214.22 Million USD | 0.01% |
| 2011 Q4 | 214.22 Million USD | 14.44% |
| 2010 Q1 | 212.73 Million USD | 15.52% |
| 2010 FY | 214.21 Million USD | 16.32% |
| 2010 Q4 | 214.21 Million USD | -2.39% |
| 2010 Q3 | 219.45 Million USD | 4.7% |
| 2010 Q2 | 209.59 Million USD | -1.47% |
| 2009 Q2 | 119.57 Million USD | 6.16% |
| 2009 FY | 184.15 Million USD | 131.01% |
| 2009 Q3 | 201.4 Million USD | 68.43% |
| 2009 Q1 | 112.64 Million USD | 41.3% |
| 2009 Q4 | 184.15 Million USD | -8.56% |
| 2008 Q4 | 79.71 Million USD | -70.84% |
| 2008 Q1 | 301.91 Million USD | 14.94% |
| 2008 Q2 | 306.02 Million USD | 1.36% |
| 2008 Q3 | 273.37 Million USD | -10.67% |
| 2008 FY | 79.71 Million USD | -69.65% |
| 2007 Q2 | 318.91 Million USD | 0.04% |
| 2007 Q4 | 262.67 Million USD | 14.19% |
| 2007 Q3 | 230.03 Million USD | -27.87% |
| 2007 FY | 262.67 Million USD | -29.83% |
| 2007 Q1 | 318.79 Million USD | -14.84% |
| 2006 Q1 | 176.27 Million USD | -0.49% |
| 2006 Q3 | 280.4 Million USD | -2.03% |
| 2006 Q4 | 374.36 Million USD | 33.51% |
| 2006 FY | 374.36 Million USD | 111.34% |
| 2006 Q2 | 286.2 Million USD | 62.36% |
| 2005 Q3 | 81.29 Million USD | -34.71% |
| 2005 FY | 177.13 Million USD | 87.15% |
| 2005 Q1 | 148.78 Million USD | 57.19% |
| 2005 Q2 | 124.51 Million USD | -16.31% |
| 2005 Q4 | 177.13 Million USD | 117.88% |
| 2004 FY | 94.65 Million USD | -71.25% |
| 2004 Q4 | 94.65 Million USD | -11.52% |
| 2004 Q3 | 106.97 Million USD | -36.93% |
| 2004 Q2 | 169.62 Million USD | 401.05% |
| 2004 Q1 | 33.85 Million USD | -89.72% |
| 2003 Q2 | 310.61 Million USD | 0.14% |
| 2003 Q1 | 310.17 Million USD | 4.39% |
| 2003 Q3 | 373.58 Million USD | 20.27% |
| 2003 FY | 329.25 Million USD | 10.81% |
| 2003 Q4 | 329.25 Million USD | -11.87% |
| 2002 Q3 | 287.77 Million USD | -6.03% |
| 2002 Q1 | 280.94 Million USD | -6.68% |
| 2002 Q4 | 297.14 Million USD | 3.26% |
| 2002 FY | 297.14 Million USD | -1.3% |
| 2002 Q2 | 306.22 Million USD | 9.0% |
| 2001 Q1 | 238.87 Million USD | 29.63% |
| 2001 Q2 | 103.31 Million USD | -56.75% |
| 2001 Q3 | 299.73 Million USD | 190.11% |
| 2001 Q4 | 301.05 Million USD | 0.44% |
| 2001 FY | 301.05 Million USD | 63.37% |
| 2000 Q4 | 184.27 Million USD | 23.23% |
| 2000 Q3 | 149.53 Million USD | -2.81% |
| 2000 Q1 | 114.86 Million USD | 43.66% |
| 2000 Q2 | 153.86 Million USD | 33.95% |
| 2000 FY | 184.27 Million USD | 130.46% |
| 1999 Q3 | -14.38 Million USD | -47.43% |
| 1999 Q4 | 79.96 Million USD | 656.05% |
| 1999 Q2 | -9.75 Million USD | 25.53% |
| 1999 Q1 | -13.09 Million USD | 34.22% |
| 1999 FY | 79.96 Million USD | 501.57% |
| 1998 FY | -19.91 Million USD | -103.95% |
| 1998 Q2 | -23.5 Million USD | -272.59% |
| 1998 Q1 | -6.3 Million USD | 35.38% |
| 1998 Q4 | -19.91 Million USD | -49.1% |
| 1998 Q3 | -13.35 Million USD | 43.19% |
| 1997 Q3 | -9.47 Million USD | 71.26% |
| 1997 FY | -9.76 Million USD | 46.36% |
| 1997 Q1 | -36.48 Million USD | -100.48% |
| 1997 Q2 | -32.98 Million USD | 9.59% |
| 1997 Q4 | -9.76 Million USD | -3.0% |
| 1996 Q1 | -1.6 Million USD | 50.0% |
| 1996 Q4 | -18.2 Million USD | -116.67% |
| 1996 Q3 | -8.4 Million USD | -9.09% |
| 1996 FY | -18.2 Million USD | -468.75% |
| 1996 Q2 | -7.7 Million USD | -381.25% |
| 1995 Q3 | -2.8 Million USD | 57.58% |
| 1995 FY | -3.2 Million USD | 67.35% |
| 1995 Q2 | -6.6 Million USD | 66.33% |
| 1995 Q1 | -19.6 Million USD | -100.0% |
| 1995 Q4 | -3.2 Million USD | -14.29% |
| 1994 FY | -9.8 Million USD | 0.0% |
| 1994 Q2 | -11.1 Million USD | -692.86% |
| 1994 Q3 | -7.6 Million USD | 31.53% |
| 1994 Q1 | -1.4 Million USD | 0.0% |
| 1994 Q4 | -9.8 Million USD | -28.95% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 475.831% |
| Alkermes plc | -166.73 Million USD | 226.089% |
| Agenus Inc. | 274.13 Million USD | 23.308% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 88.757% |
| Aptorum Group Limited | 1.35 Million USD | -15392.474% |
| Ardelyx, Inc. | 34.51 Million USD | -509.179% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | -4812.15% |
| Bicycle Therapeutics plc | -481.46 Million USD | 143.667% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | -481.368% |
| ChromaDex Corporation | -24.04 Million USD | 974.251% |
| Chimerix, Inc. | -25.51 Million USD | 923.921% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -2917.189% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 987.95% |
| CRISPR Therapeutics AG | -150.84 Million USD | 239.375% |
| Precision BioSciences, Inc. | -85.41 Million USD | 346.154% |
| Dyadic International, Inc. | -6.37 Million USD | 3396.28% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 1419.526% |
| Fortress Biotech, Inc. | 7.66 Million USD | -2642.857% |
| Lantern Pharma Inc. | -21.7 Million USD | 1068.702% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 290.199% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 2560.911% |
| Incyte Corporation | -3.17 Billion USD | 106.622% |
| IO Biotech, Inc. | -140.69 Million USD | 249.425% |
| Jaguar Health, Inc. | 29.39 Million USD | -615.321% |
| Novavax, Inc. | -298.29 Million USD | 170.481% |
| Janux Therapeutics, Inc. | 5.33 Million USD | -3839.292% |
| Opthea Limited | 28.15 Million USD | -646.659% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 1352.248% |
| ContextLogic Inc. | -232 Million USD | 190.621% |
| MiMedx Group, Inc. | -33.9 Million USD | 720.159% |
| Pyxis Oncology, Inc. | 10.19 Million USD | -1962.187% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 9173.697% |
| NextCure, Inc. | -6.47 Million USD | 3345.947% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 516.309% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 3395.814% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | -1628.483% |
| Vaxcyte, Inc. | -368.22 Million USD | 157.095% |
| PDS Biotechnology Corporation | -32.7 Million USD | 742.761% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | -1116.808% |
| Pharming Group N.V. | 109.8 Million USD | -91.468% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 1308.554% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 219.979% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 1235.214% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 1235.214% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 3061.127% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 3687.713% |
| Acelyrin, Inc. | -216.9 Million USD | 196.928% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 3847.415% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 12294.896% |
| Summit Therapeutics Inc. | 34.67 Million USD | -506.333% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 3190.401% |
| Senti Biosciences, Inc. | 1.74 Million USD | -11982.759% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 213.885% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 371.449% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 3568.162% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | -210626.779% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | -33377.707% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 279.622% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 224.97% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | -89.627% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 2867.773% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 262.833% |
| Psyence Biomedical Ltd. | 6.89 Million USD | -2949.344% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 186.746% |
| Immix Biopharma, Inc. | -17.5 Million USD | 1300.7% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 166.384% |
| MEI Pharma, Inc. | -3.7 Million USD | 5774.494% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | -1580.441% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | -29.985% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | -656.449% |
| Fortress Biotech, Inc. | 7.66 Million USD | -2642.857% |
| Precigen, Inc. | -481 Thousand USD | 43808.94% |
| Clearside Biomedical, Inc. | 14.08 Million USD | -1393.076% |
| AlloVir, Inc. | -62.69 Million USD | 435.354% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 478.034% |
| Fate Therapeutics, Inc. | 61.66 Million USD | -240.933% |
| ImmuCell Corporation | 10.99 Million USD | -1812.914% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 236.39% |
| Onconetix, Inc. | 5.33 Million USD | -3843.402% |
| PureTech Health plc | -167.19 Million USD | 225.744% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 790.217% |
| Elevation Oncology, Inc. | -19.11 Million USD | 1199.697% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 4382.746% |
| Seer, Inc. | -4.24 Million USD | 5058.491% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 974.652% |
| Innoviva, Inc. | 255.56 Million USD | 17.735% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 476.343% |
| ESSA Pharma Inc. | -33.62 Million USD | 725.313% |
| GlycoMimetics, Inc. | -40.98 Million USD | 612.975% |
| GT Biopharma, Inc. | -1.02 Million USD | 20691.577% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 410.166% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | -243.21% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 256.803% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 1617.321% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 828.18% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | 279177.176% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 781.226% |
| Aptose Biosciences Inc. | -8.19 Million USD | 2665.512% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 6819.041% |
| Soligenix, Inc. | -4.95 Million USD | 4345.903% |
| Century Therapeutics, Inc. | 847 Thousand USD | -24721.724% |
| Kura Oncology, Inc. | -20.11 Million USD | 1145.034% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 613.708% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 2603.453% |
| Ocean Biomedical, Inc. | 1.82 Million USD | -11440.9% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 6676.165% |
| Autolus Therapeutics plc | -186.59 Million USD | 212.669% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 526.416% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 176.231% |
| Eterna Therapeutics Inc. | 34.26 Million USD | -513.517% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | -27.908% |
| GRI Bio, Inc. | -1.79 Million USD | 11819.064% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 2440.409% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 732.168% |
| IGM Biosciences, Inc. | -72.6 Million USD | 389.563% |
| INmune Bio, Inc. | -25.41 Million USD | 927.358% |
| Heron Therapeutics, Inc. | 150.95 Million USD | -39.277% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 515.01% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 1393.835% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 7387.535% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | -453.045% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 610.477% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -559.37% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 44.374% |
| Verastem, Inc. | -37.27 Million USD | 663.979% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 2417.205% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 505.384% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 1489.098% |
| Histogen Inc. | -7.48 Million USD | 2908.067% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 1073.026% |
| Surrozen, Inc. | -32.66 Million USD | 743.644% |
| Organovo Holdings, Inc. | -1.5 Million USD | 14050.896% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 5101.561% |
| Ovid Therapeutics Inc. | 18.96 Million USD | -1008.849% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -7936.697% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | -4958.71% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 2608.486% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 583.956% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 1542.286% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 166.366% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | 29216.694% |
| Apollomics, Inc. | -27.39 Million USD | 867.439% |
| Amarin Corporation plc | -191.04 Million USD | 210.05% |
| Mesoblast Limited | 55.96 Million USD | -275.677% |
| Turnstone Biologics Corp. | -14.58 Million USD | 1541.58% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 931.251% |
| Synaptogenix, Inc. | -28.66 Million USD | 833.528% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | 22561.538% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | -331.421% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 24487.273% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 2993.445% |
| Exelixis, Inc. | -73.05 Million USD | 387.803% |
| Better Therapeutics, Inc. | -860 Thousand USD | 24546.512% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 975.526% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 187.102% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -28462.656% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 2926.515% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -16665.55% |
| Gritstone bio, Inc. | 39.49 Million USD | -432.388% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 349.985% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 8087.417% |
| Avid Bioservices, Inc. | 169.72 Million USD | -23.869% |
| Insmed Incorporated | 721.62 Million USD | 70.866% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 2399.838% |
| MediWound Ltd. | -5.32 Million USD | 4050.395% |
| OmniAb, Inc. | 9.2 Million USD | -2184.472% |
| Alector, Inc. | -35.63 Million USD | 689.949% |
| Seres Therapeutics, Inc. | 85.97 Million USD | -144.548% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 4366.234% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | -1488.035% |
| Zai Lab Limited | -775 Million USD | 127.128% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 38.265% |
| Aura Biosciences, Inc. | -21.52 Million USD | 1076.725% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 354.898% |
| Immunic, Inc. | -45.34 Million USD | 563.697% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 208.811% |
| Veracyte, Inc. | -203.82 Million USD | 203.148% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 67.062% |
| FibroGen, Inc. | 56.76 Million USD | -270.356% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -2260.921% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 7536.643% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 10254.815% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 95.42% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 6392.727% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 226.678% |
| TG Therapeutics, Inc. | 17.86 Million USD | -1077.024% |
| Galecto, Inc. | -21.21 Million USD | 1090.95% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 983.918% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 86.604% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 959.104% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 1927.062% |
| XBiotech Inc. | -200.02 Million USD | 205.108% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 349.985% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | -4543.11% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 696.206% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 372.268% |
| Theravance Biopharma, Inc. | 5.69 Million USD | -3594.254% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 223.369% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 327.597% |
| Vaxxinity, Inc. | 10.13 Million USD | -1975.01% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 71.445% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 2052.533% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 418.758% |
| NexImmune, Inc. | -3.13 Million USD | 6809.124% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 6189.195% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 1491.263% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 875.793% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 2442.232% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 168865.804% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 618.19% |
| Ainos, Inc. | 4.07 Million USD | -5055.559% |
| Pluri Inc. | 22.82 Million USD | -820.934% |
| Prothena Corporation plc | -608.34 Million USD | 134.559% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 277.035% |
| Celularity Inc. | 65.19 Million USD | -222.503% |
| Rallybio Corporation | -24.1 Million USD | 972.293% |
| Cue Biopharma, Inc. | -33.81 Million USD | 721.662% |
| MeiraGTx Holdings plc | -40.3 Million USD | 621.661% |
| Omeros Corporation | 331.17 Million USD | 36.517% |
| Humacyte, Inc. | -22.48 Million USD | 1034.982% |
| Immunocore Holdings plc | -358.59 Million USD | 158.629% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 955.504% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 780.366% |
| Blueprint Medicines Corporation | 702.83 Million USD | 70.087% |
| CalciMedica, Inc. | -5.53 Million USD | 3901.808% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 211.699% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 2158.351% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 625.114% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 732.244% |
| Pulmatrix, Inc. | -10.41 Million USD | 2118.239% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 3617.484% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 651.203% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 288.722% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 450.727% |
| Cytokinetics, Incorporated | 642.37 Million USD | 67.271% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 3710.51% |
| Nutriband Inc. | -251.65 Thousand USD | 83642.282% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 716.196% |
| Vor Biopharma Inc. | 4.3 Million USD | -4789.302% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 103.483% |
| Evogene Ltd. | -19.63 Million USD | 1170.796% |
| ProKidney Corp. | -56.23 Million USD | 473.853% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 531.953% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 2376.018% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 84.585% |
| CorMedix Inc. | -43.05 Million USD | 588.334% |
| BioLineRx Ltd. | 7.33 Million USD | -2765.867% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 865.483% |
| Galectin Therapeutics Inc. | 46.14 Million USD | -355.588% |
| Atai Life Sciences N.V. | -28.55 Million USD | 836.186% |
| Renovaro Biosciences Inc. | 2.23 Million USD | -9325.567% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 1021.459% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | -1085.452% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 380.044% |
| MediciNova, Inc. | -50.78 Million USD | 513.993% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 366.785% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 934707.691% |
| GeoVax Labs, Inc. | -6.45 Million USD | 3358.227% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 205.214% |
| Biomea Fusion, Inc. | -166.57 Million USD | 226.217% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 217.469% |
| Mereo BioPharma Group plc | -51.46 Million USD | 508.479% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 321.669% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 171.569% |
| Absci Corporation | -72.59 Million USD | 389.595% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -4504.468% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 189.679% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 323.159% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 319.696% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 638.07% |
| Allakos Inc. | -24.97 Million USD | 941.802% |
| Imunon, Inc. | -4.21 Million USD | 5089.259% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 1526.129% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 255.273% |
| BioAtla, Inc. | -109.01 Million USD | 292.861% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -28462.656% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 22489.776% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | -1656.978% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 1091.558% |
| XOMA Corporation | -29 Million USD | 824.966% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 1369.565% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 2431.854% |
| aTyr Pharma, Inc. | -7.44 Million USD | 2922.392% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 268.683% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 200.997% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 357.083% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 326.642% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | 24569.729% |
| Akari Therapeutics, Plc | -3.84 Million USD | 5567.88% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -12854.667% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 84.775% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 17794.959% |
| UroGen Pharma Ltd. | 4.39 Million USD | -4687.975% |
| Sutro Biopharma, Inc. | 113.48 Million USD | -85.264% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -292054.192% |
| Orgenesis Inc. | 21.78 Million USD | -865.112% |
| Entera Bio Ltd. | -10.62 Million USD | 2077.985% |
| GH Research PLC | -78.07 Million USD | 369.273% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 1043.288% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 888.627% |
| Xencor, Inc. | 29.64 Million USD | -609.216% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 10773.1% |
| Replimune Group, Inc. | 1.41 Million USD | -14789.518% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | 85944.48% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 266.307% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 17794.959% |
| Portage Biotech Inc. | -4.98 Million USD | 4320.839% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 934707.691% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 417.958% |
| OncoCyte Corporation | -6.56 Million USD | 3303.413% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | -23327.341% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 4714.936% |
| Purple Biotech Ltd. | -14.13 Million USD | 1587.056% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 984.997% |
| scPharmaceuticals Inc. | -6.54 Million USD | 3312.223% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 1359.513% |
| HilleVax, Inc. | -165.48 Million USD | 227.045% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 8383.688% |
| Tharimmune, Inc. | -10.93 Million USD | 2022.572% |
| Genprex, Inc. | -6.73 Million USD | 3220.386% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 157.005% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 337.667% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 15106.424% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 6438.361% |
| OKYO Pharma Limited | -826.84 Thousand USD | 25526.681% |
| Savara Inc. | 153 Thousand USD | -137311.765% |
| Curis, Inc. | -23.88 Million USD | 980.144% |
| Daré Bioscience, Inc. | -5.15 Million USD | 4176.069% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | 27192.365% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 3486.598% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | -17641.772% |
| BeiGene, Ltd. | -2.25 Billion USD | 109.331% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | -1603.935% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 134.567% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 213.284% |
| Erasca, Inc. | -37.21 Million USD | 664.918% |
| bluebird bio, Inc. | 108.57 Million USD | -93.643% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 16424.338% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 44.491% |
| DBV Technologies S.A. | -126.98 Million USD | 265.562% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 16424.338% |
| Moderna, Inc. | -2.9 Billion USD | 107.232% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 2130.912% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 2034.487% |
| Molecular Templates, Inc. | 707 Thousand USD | -29636.917% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 770.173% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 39.344% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 356.197% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 329.194% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 751.463% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 711.589% |
| MacroGenics, Inc. | -66.98 Million USD | 413.861% |
| RenovoRx, Inc. | -1.17 Million USD | 18023.274% |
| Adicet Bio, Inc. | -138.78 Million USD | 251.484% |
| Prime Medicine, Inc. | -27.94 Million USD | 852.443% |
| Aditxt, Inc. | 18.12 Million USD | -1060.208% |
| Adagene Inc. | -87.62 Million USD | 339.925% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 5147.26% |
| Quantum-Si incorporated | -118.55 Million USD | 277.332% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | -483.919% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 2912.881% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 533.404% |
| SciSparc Ltd. | -2.06 Million USD | 10281.114% |
| Vericel Corporation | 1.27 Million USD | -16363.587% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 1853.212% |
| Minerva Neurosciences, Inc. | 41 Million USD | -412.727% |
| Generation Bio Co. | 31.44 Million USD | -568.532% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 219.888% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 779.882% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | -80.32% |
| Invivyd, Inc. | -198.47 Million USD | 205.927% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 332.901% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 8868.446% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 396.991% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 3180.44% |
| 2seventy bio, Inc. | 181.71 Million USD | -15.698% |
| ADMA Biologics, Inc. | 90.06 Million USD | -133.429% |
| Clene Inc. | 3.34 Million USD | -6194.611% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 2414.729% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 1077.36% |
| GeoVax Labs, Inc. | -6.45 Million USD | 3358.227% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 161.094% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 908.625% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | -18.334% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 5238.374% |
| Finch Therapeutics Group, Inc. | 5 Million USD | -4103.119% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 4136.091% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 261.346% |
| Evaxion Biotech A/S | 5.28 Million USD | -3876.664% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 286.767% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 260.155% |
| Trevena, Inc. | 2.25 Million USD | -9210.895% |
| Surrozen, Inc. | -32.66 Million USD | 743.644% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 508.154% |
| Cingulate Inc. | 3.08 Million USD | -6720.033% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 7258.325% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -2825.282% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 2362.78% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 365.043% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 259.937% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 299.2% |
| Clearmind Medicine Inc. | -3.94 Million USD | 5432.472% |
| Kronos Bio, Inc. | -36.05 Million USD | 683.125% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | -2134.456% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -14318.497% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 487.496% |
| Statera Biopharma, Inc. | 14.41 Million USD | -1358.339% |
| ImmunityBio, Inc. | 618.22 Million USD | 65.993% |
| Korro Bio, Inc. | -132.94 Million USD | 258.143% |
| Kineta, Inc. | -4.54 Million USD | 4729.817% |
| BioVie Inc. | -17.73 Million USD | 1285.63% |
| Codexis, Inc. | -43.27 Million USD | 585.868% |
| Celularity Inc. | 65.19 Million USD | -222.503% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 6734.269% |
| Celcuity Inc. | 6.78 Million USD | -2999.281% |
| Virax Biolabs Group Limited | -3.36 Million USD | 6347.949% |
| Cibus, Inc. | -8.07 Million USD | 2702.624% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 5071.388% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -4500.438% |
| IN8bio, Inc. | -16.38 Million USD | 1382.812% |
| Kodiak Sciences Inc. | -103.87 Million USD | 302.397% |
| Annexon, Inc. | -193.75 Million USD | 208.508% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | -583900.0% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 1301.44% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 6084.629% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 80.058% |
| Eyenovia, Inc. | 1.25 Million USD | -16602.921% |
| Puma Biotechnology, Inc. | 26.9 Million USD | -681.416% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 6582.886% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 732.358% |
| Arcellx, Inc. | -296.95 Million USD | 170.798% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 1177.822% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 457.096% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 1114.329% |
| Moolec Science SA | 117.61 Thousand USD | -178651.19% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 647.514% |
| Geron Corporation | 14.76 Million USD | -1324.294% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 654.46% |
| Royalty Pharma plc | 5.65 Billion USD | 96.284% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 248.663% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 3107.973% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 4020.297% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 249.391% |
| Humacyte, Inc. | -22.48 Million USD | 1034.982% |
| Structure Therapeutics Inc. | -124.33 Million USD | 269.086% |
| 89bio, Inc. | -289.05 Million USD | 172.734% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 932.898% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 11891.363% |
| Genelux Corporation | -6.89 Million USD | 3147.398% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 776.905% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | -151.486% |
| Notable Labs, Ltd. | -9.77 Million USD | 2250.573% |
| Liquidia Corporation | -80.17 Million USD | 362.223% |
| Mustang Bio, Inc. | -3.73 Million USD | 5727.409% |
| Immunovant, Inc. | -635.22 Million USD | 133.097% |
| Quantum-Si incorporated | -118.55 Million USD | 277.332% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 1296.994% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 5174.584% |
| Vera Therapeutics, Inc. | 8.02 Million USD | -2519.16% |
| Acasti Pharma Inc. | -23 Million USD | 1013.888% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 6343.71% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 1393.835% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 252.635% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 6846.328% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 1045.664% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 1232.21% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 224.198% |
| PepGen Inc. | -60.67 Million USD | 446.53% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 1015.042% |
| United Therapeutics Corporation | -507.7 Million USD | 141.41% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 1199.237% |
| Solid Biosciences Inc. | -47.75 Million USD | 540.293% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 24487.273% |
| Immuneering Corporation | -54.94 Million USD | 482.652% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 5101.561% |
| Silo Pharma, Inc. | -3.52 Million USD | 6065.426% |
| Belite Bio, Inc | -87.27 Million USD | 340.905% |
| XOMA Corporation | -29 Million USD | 824.966% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 397.382% |
| Bionomics Limited | 227 Million USD | 7.387% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 280.802% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 8400.039% |
| uniQure N.V. | -102.95 Million USD | 304.214% |
| Cassava Sciences, Inc. | -121.13 Million USD | 273.557% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 5147.26% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | -413.394% |
| Forte Biosciences, Inc. | -11.96 Million USD | 1857.713% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 6894.648% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | -198239.623% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 6582.886% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -2260.921% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 2934.951% |
| Altimmune, Inc. | -134.48 Million USD | 256.327% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -6.147% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 8400.039% |
| Compugen Ltd. | -12.9 Million USD | 1729.262% |
| Peak Bio, Inc. | 10.34 Million USD | -1933.238% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | 74389.753% |
| Benitec Biopharma Inc. | -50.58 Million USD | 515.642% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 301.499% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | -970.196% |
| Zura Bio Limited | -99.8 Million USD | 310.649% |
| PolyPid Ltd. | 6.17 Million USD | -3307.455% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | -183.648% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | -970.196% |
| Instil Bio, Inc. | 75.35 Million USD | -178.988% |
| argenx SE | -2.02 Billion USD | 110.363% |
| Immunome, Inc. | -97.02 Million USD | 316.677% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 1034.608% |
| Verona Pharma plc | -220.44 Million USD | 195.372% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 393.046% |
| Shattuck Labs, Inc. | -121.42 Million USD | 273.145% |
| CervoMed Inc. | -7.79 Million USD | 2797.859% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 213.338% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 4907.684% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 259.587% |
| Moolec Science SA | 117.61 Thousand USD | -178651.19% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 9288.904% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | -1222.399% |
| AnaptysBio, Inc. | -18.15 Million USD | 1258.283% |
| Design Therapeutics, Inc. | -18.15 Million USD | 1258.347% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 398.717% |
| NeurAxis, Inc. | 145.7 Thousand USD | -144196.5% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | -1771.795% |
| Lumos Pharma, Inc. | -28.49 Million USD | 837.865% |
| Achilles Therapeutics plc | -126.92 Million USD | 265.642% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 393.046% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | 32161.977% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 1112.043% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -14318.497% |
| Nutriband Inc. | -251.65 Thousand USD | 83642.282% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 1696.234% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 2925.806% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 38.201% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | -785.78% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 146.984% |
| Palisade Bio, Inc. | -12.06 Million USD | 1842.85% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 249.839% |
| Beam Therapeutics Inc. | -262.72 Million USD | 180.024% |
| Neurogene Inc. | -131.95 Million USD | 259.327% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | -863.696% |
| AEON Biopharma, Inc. | -4.88 Million USD | 4408.197% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 155.738% |
| Sesen Bio, Inc. | -112.55 Million USD | 286.792% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 310.535% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 9054.793% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 638.718% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 352.444% |
| Athira Pharma, Inc. | -88.99 Million USD | 336.227% |
| Vaccinex, Inc. | -1.28 Million USD | 16422.981% |
| HCW Biologics Inc. | 2.85 Million USD | -7259.603% |
| XOMA Corporation | -29 Million USD | 824.966% |
| Arvinas, Inc. | -313.8 Million USD | 166.998% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -12854.667% |
| Merus N.V. | -192.88 Million USD | 208.998% |
| Omega Therapeutics, Inc. | 59.98 Million USD | -250.488% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 3130.268% |
| Rezolute, Inc. | -68.16 Million USD | 408.415% |
| Clene Inc. | 3.34 Million USD | -6194.611% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 1694.297% |
| BeyondSpring Inc. | -13.75 Million USD | 1628.462% |
| Synlogic, Inc. | -6.68 Million USD | 3244.951% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | -18439.683% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 2586.576% |
| Peak Bio, Inc. | 10.34 Million USD | -1933.238% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 355.084% |
| Krystal Biotech, Inc. | -350.23 Million USD | 160.028% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | -69.378% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 224.405% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 6759.183% |
| MannKind Corporation | 143.89 Million USD | -46.102% |
| Ikena Oncology, Inc. | -109.15 Million USD | 292.605% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 2876.912% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 735.166% |
| Gossamer Bio, Inc. | 180.35 Million USD | -16.57% |
| CohBar, Inc. | -5.93 Million USD | 3644.926% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 806.737% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -4504.468% |
| Legend Biotech Corporation | -949.39 Million USD | 122.145% |
| Mural Oncology plc | -255.84 Million USD | 182.175% |
| Biora Therapeutics, Inc. | 32.21 Million USD | -552.615% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 4563.086% |
| Disc Medicine, Inc. | -358.28 Million USD | 158.68% |
| Champions Oncology, Inc. | 4.81 Million USD | -4269.077% |
| REGENXBIO Inc. | 54.76 Million USD | -283.874% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | 78283.164% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 239.21% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 2432.888% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 360.575% |
| Vaxart, Inc. | -8.24 Million USD | 2651.147% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 518.972% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 265.328% |
| Cellectis S.A. | -43.85 Million USD | 579.398% |
| Longeveron Inc. | -2.9 Million USD | 7329.711% |
| Repare Therapeutics Inc. | -107.85 Million USD | 294.923% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 78.289% |
| Inozyme Pharma, Inc. | 12 Million USD | -1651.416% |
| Revolution Medicines, Inc. | -608.2 Million USD | 134.567% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 17192.683% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 179.301% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 240.093% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 1443.644% |
| Anixa Biosciences, Inc. | -740 Thousand USD | 28510.811% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 102.198% |
| Denali Therapeutics Inc. | -74.86 Million USD | 380.825% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 1853.212% |
| Veru Inc. | 4.77 Million USD | -4298.355% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 1969.465% |
| Cingulate Inc. | 3.08 Million USD | -6720.033% |
| Passage Bio, Inc. | 4.58 Million USD | -4485.387% |
| Context Therapeutics Inc. | -14.44 Million USD | 1554.966% |
| Exicure, Inc. | 5.84 Million USD | -3494.461% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 191.26% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 631.312% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | -1239.876% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 457.423% |
| Nuvalent, Inc. | -335.38 Million USD | 162.686% |
| ABVC BioPharma, Inc. | 1.73 Million USD | -12022.184% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 382.27% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 2464.904% |
| OmniAb, Inc. | 9.2 Million USD | -2184.472% |
| Anew Medical, Inc. | 1.43 Million USD | -14576.798% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | -1183.379% |
| Lipocine Inc. | -4.75 Million USD | 4521.831% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 291.427% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | -1280.343% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 515.01% |
| G1 Therapeutics, Inc. | 24.89 Million USD | -744.609% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 3228.106% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 419.383% |
| Ocugen, Inc. | -32.52 Million USD | 746.475% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 345.679% |
| Q32 Bio Inc. | -37.94 Million USD | 654.021% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | 33577.707% |
| Alumis Inc. Common Stock | -13.52 Million USD | 1653.995% |
| Equillium, Inc. | -22.39 Million USD | 1038.907% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 922.278% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 744.379% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | 84903.259% |
| Galera Therapeutics, Inc. | 134.04 Million USD | -56.846% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -6474.109% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -63911.497% |
| Dominari Holdings Inc. | 195 Thousand USD | -107715.385% |
| Edesa Biotech, Inc. | -5.26 Million USD | 4091.714% |
| vTv Therapeutics Inc. | -8.91 Million USD | 2457.744% |
| Bio-Techne Corporation | 267.74 Million USD | 21.478% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 1397.057% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 278.028% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 2601.964% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 1761.845% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 185.771% |
| Nkarta, Inc. | 57.29 Million USD | -266.917% |
| BioCardia, Inc. | 212 Thousand USD | -99069.811% |
| Iterum Therapeutics plc | 13.43 Million USD | -1464.519% |